Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsLieping Chen, Ingegerd Hellström, Karl Erik Hellström, Jeffrey A. Ledbetter, Peter S. Linsley
Estimating the term…
The present invention is directed to a method of inhibiting tumor cell growth. Tumor cells from a pateint are recombinantly engineered to express the B7 surface protein and these cells are then readminsistered to the pateint. The presence of the B7 molecule on the tumor cell surface stimulates a broad immunologic response against both the B7-transfected and non-transfected tumor cells and results in the immunologic killing of localized and metastatic tumor cells. B7 transfection of the tumor cells, or cell membranes, serves as a stimulant to engender a potent immunologic response against the surface antigens present on the tumor cells.
A method for generating a cytotoxic T lymphocyte response specific for cells of a tumor in a tumor-bearing patient, comprising
A method for immunizing a patient against tumor cells comprising administering B7-transfected tumor cell membranes to said patient for a time period sufficient to produce an immune response which induces a rejection response to subsequent tumor cell exposure.
A cancer therapy comprising removing aliquots of tumor cells from a tumor-bearing patient, transfecting or transducing with a retroviral vector said tumor cells with DNA encoding the B7 B cell surface protein such that said tumor cells express B7, and readministering said B7-transfected cells to the patient wherein said B7-transfected cells are costimulatory for the production of an immune response directed to the rejection of said tumor cells in the patient.
A method of inhibiting growth of a tumor in a tumor-bearing mammal, comprising administering to said tumor-bearing mammal a therapeutically effective amount of B7-transfected cells of said tumor.
Dependencies are inferred from the claim text.